Core Viewpoint - As of December 24, a total of 136 stocks in the Shanghai and Shenzhen markets have experienced net buying through financing for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Notable Financing Net Inflows - The stock with the longest consecutive net buying days is Innotek, which has seen net buying for 12 consecutive trading days [1] - Other stocks with significant consecutive net buying days include China Mobile, New Ray Energy, Industrial Fulian, High德 Infrared, Stellar Technology, Lakala, Bomin Electronics, and YK Medical [1]

Core Viewpoint - As of December 22, a total of 97 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Notable Financing Inflows - The stock with the longest consecutive net inflow is Chunzhong Technology, which has seen net buying for 12 consecutive trading days [1] - Other stocks with significant consecutive net inflows include China Mobile, Haimeixing, Srey New Materials, Debang Technology, Xinhua Co., Innotech, Zijian Electronics, and Kesen Technology [1]

Core Insights - As of December 22, a total of 86 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for 5 consecutive days or more [1] - The stocks with the longest streak of net buying are Sichuan Shuangma, Chongqing Water, and *ST Taihe, each with 13 consecutive trading days of net inflow [1] - Other notable stocks with significant net buying days include Weiteng Electric, Wujin Stainless Steel, Hangzhou High-tech, Innotek, Jiebang Technology, Meike Home, Huaxing Yuanchuang, and Ping An Bank [1]

Group 1 - The core point of the article highlights that Beijing Innotech Biotechnology Co., Ltd. has seen a net financing inflow of 26.96 million yuan last week, ranking 196th in the market [1] - The company had a total financing amount of 52.41 million yuan and repayment amount of 25.45 million yuan during the same period [1] - In the past 5 days, the main capital inflow for Innotech was 13.99 million yuan with a price increase of 6.68%, while in the past 10 days, the inflow was 11.27 million yuan with a price increase of 2.28% [2] Group 2 - Innotech operates in several concept sectors including bioproducts, Beijing sector, Shanghai Stock Connect, margin trading, smallpox virus prevention, influenza, and in vitro diagnostics [2] - The company was established in 2006 and is primarily engaged in wholesale, with a registered capital of 1.36458196 billion yuan and paid-in capital of 1.36060816 billion yuan [2] - Innotech has made investments in 9 companies, participated in 216 bidding projects, holds 33 trademark registrations, 46 patent registrations, and possesses 42 administrative licenses [2]

Core Viewpoint - The company Innotech has introduced new products that cater to both B2B and B2C markets, providing testing solutions for professional medical personnel and consumers alike [1] Product Offerings - The new product line includes a respiratory series that features combined antigen test kits for respiratory syncytial virus, adenovirus, parainfluenza virus, and others using latex chromatography [1] - Additionally, the product range includes antigen test kits for influenza A and B viruses, as well as the novel coronavirus (2019-nCoV), also utilizing latex methods [1] - Other offerings consist of fecal occult blood (FOB) test kits using colloidal gold immunochromatography and Helicobacter pylori antigen test kits employing latex methods [1]

证券日报网12月15日讯英诺特在12月9日回答调研者提问时表示，公司主要投资于与公司主营业务协同 性强的方向，具体方向包括但不限于新产品、新技术平台、新检测领域等。公司对相关项目的研判及决 策较为审慎，具体进展情况公司将按照相关监管规则及时履行信息披露义务。 （文章来源：证券日报） ...

Core Viewpoint - The company is actively developing home testing business to meet the emerging market needs across various applications, including respiratory and digestive health [1] Group 1 - The company has increased marketing efforts through its official flagship store and other online platforms [1] - The specific operational performance will be disclosed in the company's periodic reports and related announcements [1]

Core Viewpoint - The company, Innotech, has established a strong online sales channel primarily through platforms such as JD.com, Taobao, and Meituan, which supports its brand recognition in the respiratory pathogen detection field in China [1] Group 1 - The company's C-end sales channels are mainly online, including authorized stores and self-operated flagship stores on major platforms [1] - Innotech has built a certain level of brand awareness in the domestic respiratory pathogen detection market through years of technological accumulation and market expansion [1] - The established brand recognition provides a solid foundation for the company to explore new sales channels [1]

Core Viewpoint - Innotech is actively developing home testing business to meet the emerging market demand for respiratory and digestive applications, enhancing its online marketing efforts through official flagship stores and other platforms [2] Group 1: Company Overview - Innotech received an institutional research visit from Tianhong Fund on December 9, 2025, with the meeting conducted online [1] - The company’s board secretary, Chen Fukan, represented Innotech during the research meeting [2] Group 2: Product Development - Innotech's new products cater to both B-end and C-end markets, suitable for professional medical personnel and consumer self-testing [2][5] - The product lineup includes respiratory series products (e.g., combined antigen test kits for respiratory syncytial virus, adenovirus, etc.) and digestive-related products (e.g., fecal occult blood test kits, Helicobacter pylori antigen test kits) [2][6] Group 3: Sales Channels and Competitive Advantage - The C-end sales channels are primarily online, including authorized stores and self-operated flagship stores on platforms like JD.com, Taobao, and Meituan [4] - The company has established a certain level of brand recognition in the domestic respiratory pathogen detection field due to years of technical accumulation and market expansion [4] Group 4: Investment Strategy - Innotech focuses its external investments on areas that are highly synergistic with its main business, including new products, new technology platforms, and new testing fields [7] - The company conducts careful assessments and decision-making regarding related projects, with progress updates to be disclosed in accordance with regulatory requirements [7]

证券日报网讯 12月11日，英诺特在互动平台回答投资者提问时表示，国际市场拓展方面，公司进一步 丰富了东南亚市场产品矩阵，在欧洲市场取得了人绒毛膜促性腺激素（HCG）检测试剂盒（自测）、 促黄体生成素（LH）检测试剂盒（自测）两项CE（IVDR）产品注册证，系较早取得相关产品IVDR认 证的少数企业之一，实现了在欧洲市场C端业务产品布局的零的突破，在美国市场，公司取得了甲型流 感病毒/乙型流感病毒抗原检测试剂盒的FDA510（k）产品注册证，为公司突破美国市场奠定了重要基 础。公司在院端业务采取经销为主、直销为辅的销售模式，同时针对C端居家检测业务与京东、天猫、 美团等主流电商平台通过开设官方旗舰店等方式建立合作关系，未来公司将进一步扩展销售渠道，提高 品牌和产品知名度。 （文章来源：证券日报） ...